Pharma Engineering ApS: Financial statements 2023
CVR: 42133590
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Pharma Engineering ApS (CVR 42133590) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 0 and a net result of DKK -4,394 compared with DKK 5,683 the year before. Equity in the 2023 report amounted to DKK 43,472. The solvency ratio was 100%.
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -4,394
- Equity
- DKK 43,472
- Total Assets
- DKK 43,472
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 0 | -4 t. | 43 t. | 0 |
| 2022 | - | 0 | 6 t. | 48 t. | 0 |
| 2021 | - | - | 2 t. | 42 t. | 0 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Pharma Engineering ApS has published its annual report for 2022. Gross profit came to DKK 0, and the net result was DKK 5,683.
About Pharma Engineering ApS
Pharma Engineering ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2021. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Mads Mose Onsberg. The company is owned by Mads Mose Onsberg. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 6,370 compared with DKK 1,475 the year before. Equity in the 2025 report amounted to DKK 51,317.